[Biochemical aspects of modified, transdermal replacement hormone therapy].
OBJECTIVE
The aim of the study is to evaluate the influence of modified, transdermal, hormone replacement therapy [HRT] and hormone supplement therapy [HST] on concentration of FSH , LH, E1, E2, PR, IGF1, GH and bone density of lumbar vertebrae in women with osteopenia in postmenopausal period.


METHODS
65 women were enrolled, aged from 43 to 58, divided into three groups based on a randomized list. Group I control used transdermal placebo, group II used transdermal hormonal therapy [HRT] and group III used hormonal therapy per oss [HST]. The concentrations of hormones were estimate by radioimmunoenzymatic methods. Statistic analysis was based on Statistical PL.


RESULTS
After transdermal hormonal therapy [HRT], the concentration of hormones is normalized and there is a significant increase of bone density of lumbar vertebrae. Hormonal supplement therapy per oss [HST]. There is the decrease of IGF1, BMD, and increase of concentrations of estrogens, prolactin, GH.


CONCLUSIONS
1. Transdermal, hormone replacement therapy [HRT] modulates concentration of sex hormones and bone metabolism. 2. Hyperestrogenism, hyperprolactinemia, decreased IGF1 concentration and low mineral density in women after HST may cause disorders of chemical estrogens metabolism.
Stanosz
Stanisław
S
Pracownia Menopauzy i Andropauzy Pomorskiej Akademii Medycznej w Szczecinie.
Zochowska
Ewa
E
Stanosz
Małgorzata
M
D000279:Administration, Cutaneous; D000328:Adult; D000704:Analysis of Variance; D015519:Bone Density / Q000187:drug effects; D004964:Estriol / Q000097:blood; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004970:Estrone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D008159:Lumbar Vertebrae / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D016896:Treatment Outcome
D006065:Gonadotropins, Pituitary; D004970:Estrone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D004964:Estriol